About this trial
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Eligibility criteria
Qualifiers
Patients must be less than 22 years of age at the time of study enrollment
Patient has known or suspected relapsed/refractory (including primary refractory) AML as defined in protocol
This includes isolated myeloid sarcoma
Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome (ML-DS)
Disqualifiers
None
Trial design
Treatments tested in this trial
- Biospecimen Collection
Treatment groups
Locations
183Sponsors and collaborators
PedAL BCU, LLC
Lead sponsor
Children's Oncology Group
Collaborator
National Cancer Institute (NCI)
Collaborator